EYNZYMES IN HEART

初步研究表明，新药多硝基白蛋白 (PNA)对动物的大脑损伤提供了前所未有的保护 局灶性脑缺血/再灌注(卒中)模型。PNA治疗在 再灌流的开始基本上提供了完全的保护 脑部受损。因为在许多方面都有相似之处 不同器官再灌流损伤的病理生理学 心肌缺血/再灌注损伤是发病率和死亡率的主要病例。 死亡率，该公司建议测试PNA是否提供类似的 心中的保护。 建议的商业应用：心肌缺血/再灌注损伤 这是导致发病率和死亡率的主要原因。如果SynZyme被证明有 保护心脏免受这种损伤的有效性，潜在的临床应用 应用将包括在急性溶栓治疗中使用辅助药物 心肌梗死，心脏手术心脏停搏后再灌注， 和冠状动脉血管成形术。

A preliminary study has demonstrated that the new drug polynitroxyl albumin (PNA) gives unprecedented protection against brain damage in an animal model of focal cerebral ischemia/reperfusion (stroke). PNA treatment at the onset of reperfusion provided essentially complete protection against brain damage. Because there are general similarities in the pathophysiology of reperfusion injury in different organs, and because myocardial ischemia/reperfusion injury is a leading case of morbidity and mortality, the Company proposes to test whether PNA offers similar protection in the heart. PROPOSED COMMERCIAL APPLICATION: Myocardial ischemia/reperfusion injury is a leading cause of morbidity and mortality. If SynZyme were proven to have efficacy in protecting the heart against this injury, potential clinical applications would include use an adjunct to thrombolytic therapy in acute myocardial infarction, post-cardioplegia reperfusion in cardiac surgery, and coronary angioplasty.